Effectiveness of Tick-borne Encephalitis Vaccines in Children, Latvia, 2018–2020

Abstract

Background: Tick-borne encephalitis (TBE) is an infection by the tick-borne encephalitis virus (TBEV) with symptoms of central nervous system inflammation. TBE is endemic in Latvia and other parts of Europe. TBE vaccination is recommended for children in Latvia. TBE vaccine effectiveness (VE) was estimated in Latvia, a country with high TBE incidence, providing the first VE estimates against a range of TBEV infection outcomes in children 1–15 years-of-age. Methods: Rīga Stradinš University conducted nationwide surveillance for suspected TBE cases. Serum and cerebrospinal fluid were ELISA tested for TBEV-specific IgG and IgM antibodies. A fully vaccinated child was an individual who had received the 3-dose primary series and appropriately timed boosters. The proportion of laboratory-confirmed TBE cases fully vaccinated (PCV) was determined from interviews and medical records. The proportion of the general population fully vaccinated (PPV) was determined from national surveys conducted in 2019 and 2020. TBE VE in children 1–15 years-of-age was estimated using the screening method: VE = 1 − [PCV/(1 − PCV)/PPV/(1 − PPV)]. Results: From 2018 to 2020, surveillance identified 36 TBE cases in children 1–15 years-of-age; all were hospitalized, 5 (13.9%) for >12 days. Of the TBE cases, 94.4% (34/36) were unvaccinated compared with 43.8% of children in the general population. VE against TBE hospitalization in children 1–15 years-of-age was 94.9% (95% confidence interval 63.1–99.3). In 2018–2020, vaccination in children 1–15 years-of-age averted 39 hospitalized TBE cases. Conclusion: Pediatric TBE vaccines were highly effective in preventing TBE in children. Increasing TBE vaccine uptake in children is essential to maximize the public health impact of TBE vaccination.